Hollis D. Showalter

3.9k total citations · 1 hit paper
89 papers, 3.1k citations indexed

About

Hollis D. Showalter is a scholar working on Molecular Biology, Organic Chemistry and Infectious Diseases. According to data from OpenAlex, Hollis D. Showalter has authored 89 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Molecular Biology, 33 papers in Organic Chemistry and 15 papers in Infectious Diseases. Recurrent topics in Hollis D. Showalter's work include Cancer therapeutics and mechanisms (14 papers), Ubiquitin and proteasome pathways (11 papers) and Biochemical and Molecular Research (8 papers). Hollis D. Showalter is often cited by papers focused on Cancer therapeutics and mechanisms (14 papers), Ubiquitin and proteasome pathways (11 papers) and Biochemical and Molecular Research (8 papers). Hollis D. Showalter collaborates with scholars based in United States, United Kingdom and Israel. Hollis D. Showalter's co-authors include Paul D. Kirchhoff, George A. Garcia, Terri L. Boehm, Roderick J. Sorenson, Alan J. Kraker, Nouri Neamati, Nicholas J. Donato, Tomasz Cierpicki, Ting Yu and Zepeng Yao and has published in prestigious journals such as Journal of the American Chemical Society, Nucleic Acids Research and Nature Communications.

In The Last Decade

Hollis D. Showalter

88 papers receiving 3.0k citations

Hit Papers

1 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lipid storage disorders block lysosomal trafficking by inhibiting a TRP channel and lysosomal calcium release

2012 386 citations Hollis D. Showalter et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hollis D. Showalter United States	31	1.8k	853	368	354	337	89	3.1k
Frank J. Schoenen United States	27	1.5k 0.9×	668 0.8×	290 0.8×	398 1.1×	52 0.2×	76	3.0k
Angela Nebbioso Italy	41	4.0k 2.2×	678 0.8×	840 2.3×	565 1.6×	259 0.8×	127	6.0k
Daniel A. Bachovchin United States	34	4.1k 2.3×	1.1k 1.3×	1.0k 2.8×	283 0.8×	83 0.2×	54	5.5k
Ching‐Shih Chen United States	44	4.7k 2.6×	915 1.1×	1.0k 2.8×	521 1.5×	189 0.6×	144	6.8k
Silvia Schenone Italy	43	2.5k 1.4×	3.1k 3.6×	737 2.0×	234 0.7×	108 0.3×	236	5.9k
Jeffrey M. Besterman United States	42	4.2k 2.4×	608 0.7×	1.2k 3.2×	200 0.6×	100 0.3×	98	5.5k
Jef K. De Brabander United States	37	2.1k 1.2×	1.8k 2.1×	440 1.2×	440 1.2×	126 0.4×	97	4.6k
Hoyun Lee Canada	28	1.5k 0.8×	881 1.0×	334 0.9×	373 1.1×	91 0.3×	64	2.5k
Andrew D. Napper United States	22	1.3k 0.7×	311 0.4×	324 0.9×	369 1.0×	185 0.5×	53	2.4k
Shenping Liu United States	21	1.2k 0.7×	351 0.4×	439 1.2×	240 0.7×	44 0.1×	39	2.1k

Countries citing papers authored by Hollis D. Showalter

Since Specialization

Citations

This map shows the geographic impact of Hollis D. Showalter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hollis D. Showalter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hollis D. Showalter more than expected).

Fields of papers citing papers by Hollis D. Showalter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hollis D. Showalter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hollis D. Showalter. The network helps show where Hollis D. Showalter may publish in the future.

Co-authorship network of co-authors of Hollis D. Showalter

This figure shows the co-authorship network connecting the top 25 collaborators of Hollis D. Showalter. A scholar is included among the top collaborators of Hollis D. Showalter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hollis D. Showalter. Hollis D. Showalter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

McDonald, Alex J., Deborah R. Leon, Bei Wu, et al.. (2019). Altered Domain Structure of the Prion Protein Caused by Cu2+ Binding and Functionally Relevant Mutations: Analysis by Cross-Linking, MS/MS, and NMR. Structure. 27(6). 907–922.e5. 27 indexed citations

Bankhead, Armand, et al.. (2018). Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer. Pharmacology & Therapeutics. 195. 111–131. 147 indexed citations

Carpenter, Colleen, Alexander G. Zestos, Roderick J. Sorenson, et al.. (2017). Direct and Systemic Administration of a CNS-Permeant Tamoxifen Analog Reduces Amphetamine-Induced Dopamine Release and Reinforcing Effects. Neuropsychopharmacology. 42(10). 1940–1949. 23 indexed citations

Gibbons, Garrett S., Hollis D. Showalter, & Zaneta Nikolovska‐Coleska. (2015). Novel Carboxaldehyde Mediated Synthetic Pathway for 5′-Amino Adenosine Analogues. Nucleosides Nucleotides & Nucleic Acids. 34(5). 348–360. 1 indexed citations

Peterson, Luke F., Hanshi Sun, Yi‐Hong Liu, et al.. (2015). Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies. Blood. 125(23). 3588–3597. 101 indexed citations

Gonzalez-Hernandez, Marta J., Anupama Pal, Hollis D. Showalter, et al.. (2014). Chemical Derivatives of a Small Molecule Deubiquitinase Inhibitor Have Antiviral Activity against Several RNA Viruses. PLoS ONE. 9(4). e94491–e94491. 30 indexed citations

Gonzalez-Hernandez, Marta J., et al.. (2014). Small Molecule Deubiquitinase Inhibitors Promote Macrophage Anti-Infective Capacity. PLoS ONE. 9(8). e104096–e104096. 14 indexed citations

Titchenell, Paul M., et al.. (2013). Synthesis and structure–activity relationships of 2-amino-3-carboxy-4-phenylthiophenes as novel atypical protein kinase C inhibitors. Bioorganic & Medicinal Chemistry Letters. 23(10). 3034–3038. 11 indexed citations

Xu, Hao, Paul D. Kirchhoff, Tomasz Cierpicki, et al.. (2012). Structure-Based Design of Novel Benzoxazinorifamycins with Potent Binding Affinity to Wild-Type and Rifampin-Resistant Mutant Mycobacterium tuberculosis RNA Polymerases. Journal of Medicinal Chemistry. 55(8). 3814–3826. 24 indexed citations

10.

Perry, Jeffrey W., et al.. (2012). Antiviral Activity of a Small Molecule Deubiquitinase Inhibitor Occurs via Induction of the Unfolded Protein Response. PLoS Pathogens. 8(7). e1002783–e1002783. 70 indexed citations

11.

Grembecka, Jolanta, Shihan He, Aibin Shi, et al.. (2012). Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nature Chemical Biology. 8(3). 277–284. 325 indexed citations

12.

Okawada, Manabu, Hiroyuki Koga, Scott D. Larsen, et al.. (2011). Use of Enterally Delivered Angiotensin II Type Ia Receptor Antagonists to Reduce the Severity of Colitis. Digestive Diseases and Sciences. 56(9). 2553–2565. 21 indexed citations

13.

Kampf, Jeff W., et al.. (2010). A novel synthesis of 3-(substituted)pyrimido[4,5-c]pyridazine-5,7(1H,6H)-diones. Tetrahedron Letters. 51(9). 1326–1328. 15 indexed citations

14.

Aristoff, Paul A., George A. Garcia, Paul D. Kirchhoff, & Hollis D. Showalter. (2010). Rifamycins – Obstacles and opportunities. Tuberculosis. 90(2). 94–118. 140 indexed citations

15.

Showalter, Hollis D., et al.. (2009). A novel synthesis of N1-(substituted)-pyrimido[5,4-e]-1,2,4-triazine-5,7(1H,6H)-diones. Tetrahedron Letters. 50(17). 1996–1997. 4 indexed citations

16.

Tran, Tuan P., Edmund L. Ellsworth, Joseph P. Sanchez, et al.. (2006). Structure–activity relationships of 3-aminoquinazolinediones, a new class of bacterial type-2 topoisomerase (DNA gyrase and topo IV) inhibitors. Bioorganic & Medicinal Chemistry Letters. 17(5). 1312–1320. 42 indexed citations

17.

Kraker, Alan J., Brian G. Hartl, Aneesa M. Amar, et al.. (2000). Biochemical and cellular effects of c-Src kinase-selective pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. Biochemical Pharmacology. 60(7). 885–898. 121 indexed citations

18.

Hamby, James M. & Hollis D. Showalter. (1999). Small Molecule Inhibitors of Tumor-Promoted Angiogenesis, Including Protein Tyrosine Kinase Inhibitors. Pharmacology & Therapeutics. 82(2-3). 169–193. 59 indexed citations

19.

Showalter, Hollis D. & Alan J. Kraker. (1997). Small molecule inhibitors of the platelet-derived growth factor receptor, the fibroblast growth factor receptor, and Src family tyrosine kinases. Pharmacology & Therapeutics. 76(1-3). 55–71. 30 indexed citations

20.

Nordblom, Gerald D., et al.. (1989). Development of a radioimmunoassay for the anthrapyrazole chemotherapy agent CI-937 and the pharmacokinetics of CI-937 in rats.. PubMed. 49(19). 5345–51. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact